This systematic review pooled 48 randomised trials totalling 48,765 patients with type 2 diabetes, comparing SGLT2 inhibitors against placebo or active comparators for gastrointestinal neoplasms.
There was no association overall (OR 1.10, 95% CI 0.84-1.44, I-squared 0%). Site-specific analyses were all non-significant: oesophageal 1.12, gastric 1.20, hepatic 0.62, pancreatic 0.91, colonic 1.28, colorectal 0.76 and rectal 0.98. Subgroup analyses by agent, age, BMI, HbA1c, duration and dose found nothing either.
The caveats are the point. About half the trials followed patients for a year or less, event counts were low, and neoplasms were captured as reported adverse events rather than centrally adjudicated cancer endpoints, which is a weaker form of ascertainment. Cancers that take years to appear cannot show up in trials that short. This is a reasonable answer to a worried patient asking whether their SGLT2 inhibitor causes cancer, and it is not evidence of long-term oncological safety. Continue routine age-appropriate cancer screening; do not treat this as a reason to relax it.
- 48 trials, 48,765 patients, odds ratio 1.10 (95% CI 0.84-1.44) overall
- No signal at any individual gastrointestinal site
- Half the trials ran a year or less; events were captured as adverse events, not adjudicated
- Useful for reassuring a worried patient; not a substitute for routine screening
The statistics, in plain English
An I-squared of 0% means the trials agreed with one another almost exactly, so the pooled estimate is not an average of conflicting results. But agreement is not the same as power: with few events the interval stays wide, and 0.84 to 1.44 still admits a 44% relative increase. The honest reading is no signal detected, rather than no risk.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for diabetes & endocrinology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free